Jobs
-
Vectura will license dry powder formulation technology to GlaxoSmithKline for use in respiratory products for up to £20 million. The deal is for worldwide rights and is non-exclusive. Read the company’s press release. Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.